|Articles|May 9, 2022

What's new on Contemporary Pediatrics: May 9 to 13

A look at what to expect from Contemporary Pediatrics this week

Pediatric health care providers understand that eating disorders are not lifestyle choices but life-threatening mental health conditions.

A look at the symptoms of seborrheic dermatitis and the current methods available to treat it.

Plus, Dr. Tan welcomes the newest members of the editorial advisory board and bids a fond farewell to a long-serving member.

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related to this article

September 16th, 2026

Updated AAP guidance changes iron deficiency screening and treatment in children

Melissa Wallach, MD, FAAP, discusses what pediatricians should know about updated screening, supplementation, and treatment recommendations for iron deficiency.

September 16th, 2026

Bifidobacterium-based synbiotic shows safety and gut colonization in infants and toddlers

A Bifidobacterium-based synbiotic was well tolerated and increased colonization of administered strains in infants and toddlers.

September 15th, 2026

Atopic dermatitis linked to higher ADHD risk in children, with sleep disturbance emerging as key factor

Children with atopic dermatitis have higher ADHD risk, particularly with early, severe disease and sleep disturbance, a review found.

September 15th, 2026

Disease severity, phenotype predict systemic treatment response in pediatric alopecia areata

Baseline severity and clinical phenotype may help predict response to systemic therapy in children with alopecia areata.

September 14th, 2026

Teen sports supplements: What to recommend, use with caution, and avoid

Pediatricians can help teen athletes navigate sports supplements by prioritizing nutrition and identifying products to support, limit, or avoid.

September 14th, 2026

Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial

Phase 3 CROSSING trial data show tezepelumab improved histologic remission and dysphagia versus placebo through week 52 in EoE.

September 14th, 2026

FDA approves apitegromab-mstn as first muscle-targeted therapy for spinal muscular atrophy

FDA approved apitegromab-mstn (Isembyld) for SMA in patients 2 years and up, based on phase 3 data showing added motor gains with SMN2 therapy.

September 11th, 2026

FDA approves leniolisib for children aged 4 to 11 with APDS

The FDA approved 40 mg and 50 mg twice-daily leniolisib (Joenja) for children ages 4 to 11 years weighing at least 27 kg with activated PI3Kδ syndrome.